Barinthus Biotherapeutics (BRNS) Asset Writedowns and Impairment (2024 - 2025)
Barinthus Biotherapeutics (BRNS) reported Asset Writedowns and Impairment of $1.1 million for Q4 2025, down 78.57% on a YoY basis from $5.3 million in Q4 2024, and down 75.85% quarter-over-quarter from $4.7 million in Q3 2025.
Barinthus Biotherapeutics (BRNS) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Barinthus Biotherapeutics has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $1.1 million in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 78.57% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $11.1 million (changed N/A YoY), and the FY2025 full-year result was $5.8 million, up 10.15% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $1.1 million, down from $4.7 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $5.3 million in Q4 2024, with the low at $1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 4.67 Mn |
| Sep 30, 2025 | 4.67 Mn |
| Dec 31, 2024 | 5.26 Mn |
| Dec 31, 2024 | 5.26 Mn |